Two patients moved from a pig kidney to a human one

eGenesis published a clinical update on 3 September 2026 covering all five patients who have received its gene-edited pig kidney, EGEN-2784, under expanded access at Mass General Brigham since March 2024. Three sustained kidney function for more than eight months without dialysis, one of them past nine months. Two were then transplanted with human donor kidneys — which the company describes as the first reported transitions from xenotransplantation to allotransplantation.

One of those two cases, Tim Andrews, was published separately in The Lancet and is covered in its own pulse. What is new here is the rest of the cohort: a second transition, and the durability numbers across all five recipients rather than one.

That distinction is the argument. A single patient bridged to a human organ is a case report. Two out of five, with three grafts running past eight months, starts to describe a rate — the thing a transplant service would need before it could plan around the approach.

Five patients is still a small number, the data are the company’s own, and no peer-reviewed publication covers the cohort. eGenesis says an FDA-cleared trial called RESTORE, enrolling 33 waitlisted patients aged 50 to 70, is due to begin in the first quarter of 2027.